Article

Levonorgestrel-releasing Intrauterine Device is an Efficacious Contraceptive for Women with Leiomyoma.

Women's Hospital, College of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
The Journal of international medical research (Impact Factor: 1.1). 10/2012; 40(5):1966-72. DOI: 10.1177/030006051204000538
Source: PubMed

ABSTRACT To evaluate the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) as contraception for women with uterine leiomyoma.
Thirty women with uterine leiomyoma requiring contraception were enrolled and had a LNG-IUD inserted. Menstrual blood volume (assessed by a pictorial blood loss assessment chart [PBAC]), haemoglobin concentration, volume of uterus and leiomyoma were determined before and after LNG-IUD insertion.
The median (range) PBAC score was 145.0 (60.0 - 232.0) before LNG-IUD insertion, which significantly decreased to 44.0 (0.0 - 99.0) and 36.0 (0.0 - 90.0) after 6 and 12 months of LNG-IUD use, respectively. Prior to LNG-IUD insertion, the median haemoglobin concentration in patients with anaemia was 100.0 (69.0 - 109.0) g/l and this increased significantly after 6 and 12 months of LNG-IUD use, to 117.5 (101.0 - 131.0) g/l and 119.5 (108.0 - 135.0) g/l, respectively. There were no significant changes in uterine or leiomyoma volumes. No patient became pregnant and there were no severe side-effects; one IUD was expulsed.
The LNG-IUD may be a safe and effective contraceptive for women of reproductive age with uterine leiomyoma.

1 Follower
 · 
61 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 20 micrograms/24 hours levonorgestrel-releasing intrauterine contraceptive device (LNG-IUD) has, in an open randomized multicenter study, been compared to the copper-releasing device Nova T during 5 years of use; 1821 women had the LNG-IUD and 937 women had the Nova T inserted. The 5-year cumulative gross pregnancy rate was 5.9% for Nova T and 0.5% for the LNG-IUD. The local effect of levonorgestrel in the uterine cavity causes reduction of menstrual blood loss and development of oligo-amenorrhea, and the termination rates because of heavy and/or prolonged menstrual flow were significantly (P < 0.001) lower among LNG-IUD users. However, the gross termination rate because of amenorrhea was 6.0 in this group. Hb increased during use of the LNG-IUD and decreased during Nova T use, and the difference between the devices was statistically significant. The incidence of pelvic inflammatory disease (PID) was low in LNG-IUD users regardless of age, whereas in the Nova T group, the PID rate was increased among the youngest women, which makes the difference between the devices significant (P < 0.01). The gross termination rate for reasons considered to be hormonal was 12.1 in the LNG-IUD group compared to 2.0 in the Nova T group (P < 0.001). The LNG-IUD is a long-acting reversible contraceptive method for 5 years with a pregnancy rate comparable to female sterilization. The incidence of PID is low even in young women. In addition, the positive health effects such as decreased menstrual blood loss and increased blood haemoglobin concentration make the LNG-IUD a favorable combination of hormonal and intrauterine contraception.
    Contraception 01/1994; 49(1):56-72. DOI:10.1016/0010-7824(94)90109-0 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective menstrual blood loss measurements (in ml) were compared with the score obtained from a pictorial blood loss assessment chart (PBAC) which took into account the degree to which each item of sanitary protection was soiled with blood as well as the total number of pads or tampons used. Twenty eight women used the chart during 55 menstrual cycles and a single observer assessed 122 cycle collections in a similar manner. A pictorial chart score of 100 or more, when used as a diagnostic test for menorrhagia, was found to have a specificity and sensitivity of greater than 80%. Demonstration of the relation between self assessed pictorial chart scores and the objective measurement of blood loss enables us to provide a simple, cheap and reasonably accurate method of assessing blood loss before embarking upon treatment.
    British Journal of Obstetrics and Gynaecology 09/1990; 97(8):734-9. DOI:10.1111/j.1471-0528.1990.tb16249.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared proliferative activity and levels of steroid receptors in the myometrium and myoma nodes in patients with uterine myoma in different phases of menstrual cycle. Maximum proliferative activity was observed at the periphery of myoma nodes in the the secretory phase of the cycle. The content of progesterone receptors at the periphery and in the center of myoma nodes was lower in the proliferative phase of the cycle than in the secretory phase. Steroid regulation of proliferative activity in the myoma nodes in the the secretory phase through modulation of the content of progesterone receptors is hypothesized.
    Bulletin of Experimental Biology and Medicine 11/2003; 136(4):396-8. DOI:10.1023/B:BEBM.0000010962.35909.a1 · 0.37 Impact Factor

Preview

Download
4 Downloads
Available from